DOCSLIB.ORG

Lebrikizumab Program Update October 17, 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lebrikizumab Program Update October 17, 2019 Lebrikizumab Program Update October 17, 2019 DERMIRA | LEBRIKIZUMAB PROGRAM UPDATE – OCTOBER 2019 DERMIRA | LEBRIKIZUMAB PROGRAM UPDATE – OCTOBER 2019 Forward-looking statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward- looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our vision for lebrikizumab, business strategy, objectives, opportunities and plans; timing expectations for the Phase 3 lebrikizumab clinical trial; the targeted profile, attributes and performance for lebrikizumab; and lebrikizumab’s potential to be a best-in-disease therapy for the treatment of atopic dermatitis. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements, including, but not limited to, those related to our dependence on third-party clinical research organizations, manufacturers, suppliers and distributors; the outcomes of future meetings with regulatory agencies; our ability to obtain necessary additional capital; market acceptance of our product; the impact of competitive products and therapies; our ability to attract and retain key employees; the costs of our commercialization plans and development programs; the design, implementation and outcomes of our clinical trials; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with our material contractual obligations, applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings we make with the Securities and Exchange Commission (SEC) from time to time for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update any forward-looking statements after the date of this presentation except as may be required by law. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Projections, assumptions and estimates of the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. We use our website (www.dermira.com), LinkedIn page (www.linkedin.com/company/dermira-inc-), Instagram account and corporate Twitter account (@DermiraInc) as channels of distribution of information about our company, product candidates, planned announcements, attendance at upcoming conferences and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website, LinkedIn page, Twitter account and Instagram page in addition to following our SEC filings, press releases, public conference calls and webcasts. DERMIRA | LEBRIKIZUMAB PROGRAM OVERVIEW 2 Dermira Vision for Lebrikizumab (Lebri) Potential to deliver best-in-disease therapy to atopic dermatitis (AD) patients and those who care for them There will be a large market for safe, AD is projected to become the largest Lebri may present an opportunity effective and convenient α-IL-4/13 market in dermatology. to address key market needs. biologics. • Driven by the advent of new, systemic • α-IL-4/13 biologics are establishing the • The market is and will remain ripe for therapies addressing unmet needs in market and treatment paradigm. improvements on initial systemics, moderate-to-severe patients, major- • While other approaches have shown including in efficacy, tolerability and market sales of branded, systemic promise, their full profiles and suitability convenience. therapies for AD are projected to exceed for broad adoption remain to be seen. • Clinical data suggest lebri may deliver $21B by 2027.1 • Ultimately, the scale of the market and these improvements together with the patient needs will support a range of safety of the α-IL-4/13 class. products. 1. Decision Resources (2018) Landscape & forecast: Atopic dermatitis/ Eczema. DERMIRA | LEBRIKIZUMAB PROGRAM UPDATE – OCTOBER 2019 3 AD Insights Following EADV 2019 What We Heard • Excitement from the dermatology community about the focus on innovation being made in AD, given the high unmet need • Continued enthusiasm for the IL-4/13 class as a new standard of care with broad efficacy and favorable safety • Focus on opportunities for improvements in key areas including: • Efficacy, particularly in itch, given the significant burden of this symptom on patients • Tolerability, particularly in view of high rates of conjunctivitis observed with dupilumab • Convenience, particularly less frequent dosing What We Saw • Consistent with what we expected based on previously reported data • Most relevant new disclosures were for JAK inhibitors • Despite efficacy, comparable to lebri, at high doses in certain cases, safety risks and tolerability challenges remain • While JAK inhibitors may play a role in a market as large and diverse as AD is expected to become, utilization may be limited, relative to that of IL-4/13 biologics DERMIRA | LEBRIKIZUMAB PROGRAM UPDATE – OCTOBER 2019 4 Phase 2b Study Results April W. Armstrong, MD, MPH Professor of Dermatology and Associate Dean of Clinical Research, University of Southern California Keck School of Medicine Lebrikizumab Study Investigator Lebrikizumab, a High Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to- Severe Atopic Dermatitis: Primary Results From a Randomized, Double‐Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study E. Guttman-Yassky,1 A. Blauvelt,2 L. Eichenfield,3 A. Paller,4 A. Armstrong,5 J. Drew,6 R. Gopalan,6 E. Simpson7 1Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Oregon Medical Research Center, Portland, OR, USA; 3Department of Dermatology and Pediatrics, University of California, San Diego, CA, USA, and Rady Children's Hospital, San Diego, CA, USA; 4Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 5Department of Dermatology, Keck School of Medicine at University of Southern California, Los Angeles, CA, USA; 6Dermira, Inc., Menlo Park, CA, USA; 7Department of Dermatology, Oregon Health and Science University, Portland, OR, USA DERMIRA | LEBRIKIZUMAB PROGRAM UPDATE – OCTOBER 2019 DERMIRA | LEBRIKIZUMAB PROGRAM UPDATE – OCTOBER 2019 IL-13 is a Central Pathogenic Mediator in AD 1Brunner PM et al. J Allergy Clin Immunol. 2017;139:S65-76; 2Buzney CD et al. J Drugs Dermatol. 2016;15:165-71; 3Brandt EB et al. J Clin Cell Immunol. 2011;10:doi:10.4172/2155-9899.1000110; 4May RD et al. Cytokine. 2015;75:89-116; 5Purwar R et al. J Invest Dermatol. 2006;126:1043- 51; 6Sebire G et al. Cytokine. 1996;8:636–41; 7Oetjen LK et al. Cell. 2017;171:http://dx.doi.org/10.1016/j.cell.2017.08.006 AD, atopic dermatitis; IL, interleukin DERMIRA | LEBRIKIZUMAB PROGRAM UPDATE – OCTOBER 2019 7 Lebrikizumab Mechanism of Action Lebrikizumab IL-13 IL-13Rα1 IL-4Rα TYK2 JAK1 IL-13Rα2 STAT 6 “Decoy” P Lebrikizumab is a novel, high-affinity monoclonal antibody targeting IL-13 that selectively prevents formation of the IL-13Rα1/IL-4Rα heterodimer receptor signaling complex while leaving endogenous regulation of IL-13 intact DERMIRA | LEBRIKIZUMAB PROGRAM UPDATE – OCTOBER 2019 8 Study Design 250 mg LD Wk 0 LEB 125 mg Q4W, n=73 500 mg LEB 250 mg Q4W, n=80 3:3:3:2 LD Wk 0 Randomization Safety follow- N=280 500 mg LD up to Week 32 Wk 0 & 2 LEB 250 mg Q2W, n=75 Placebo Q2W, n=52 Screening (≤30 days) Randomized, Double-Blind Treatmenta Week 0 Week 4 Week 8 Week 12 Week 16 Week 32 Key inclusion criteria Concomitant therapies Key endpoints • Adults with moderate-to-severe AD inadequately • TCS, TCI and prescription • Primary: % change in EASI from Baseline at Wk 16 controlled with topicals or for whom topical treatment is moisturizers washed out ≥1 wk prior • Secondary: medically inadvisable to Baseline − Skin lesions: IGA 0/1, EASI50/75/90 b − Chronic AD for ≥ 1 y • OTC emollient used bid for ≥1 wk − Pruritus: Pruritus NRS change ≥4 points and − EASI ≥16 prior to Baseline and duration of study % change from Baseline − IGA score ≥3 (5-point scale [0-4]) • Medications known to affect AD only − ≥10% BSA involvement used as rescue therapies aPatients were seen every two weeks and received all study drug injections in the clinic; bAs defined by Hanifin and Rajka AD, atopic dermatitis; bid, twice daily; BSA, body surface area; EASI, Eczema Area and Severity Index; EASI50/75/90, ≥50%/75%/90% improvement from Baseline in EASI; IGA, Investigator’s Global Assessment; IGA 0/1, score of 0 ‘clear’ or 1 ‘almost clear’ IGA from Baseline; LEB, lebrikizumab; LD, loading dose; NRS, numeric rating scale; OTC, over-the-counter; Q2W, every 2 weeks; Q4W, every 4 weeks; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids; Wk, week DERMIRA | LEBRIKIZUMAB PROGRAM UPDATE – OCTOBER 2019 9 Patient Demographics and Baseline Disease Characteristics Placebo Q2W LEB 125 mg Q4W LEB 250 mg Q4W LEB 250 mg Q2W n=52 n=73 n=80 n=75 Age, mean (SD), years 42.2 (18.2) 36.7 (16.5) 40.2 (17.9) 38.9 (17.4) Male, no. (%) 28 (53.8) 27 (37.0) 33 (41.3) 26 (34.7) Race, no.
Load more

Recommended publications
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • BIOLOGIC THERAPIES ASTHMA DYKEWICZ F BW.Pdf
    11/30/2011 Biologic Asthma Therapies and Individualized Medicine Disclosures Advisory boards Mark S. Dykewicz, MD Merck (advisor, honorarium) Director, Allergy & Immunology Shire (advisor, honorarium) Fellowship Program Director Wake Forest University School of Medicine Editorial boards Winston-Salem, North Carolina USA Allergy & Asthma Proceedings American Journal of Rhinology & Allergy Clinical Reviews in Allergy & Immunology Journal of Angioedema Learning Objective Biological therapies May fill unmet needs, potentially in To better understand the use of biologic subpopulations or phenotypes of patients with modifiers in individualized asthma more severe asthma. treatment. May provide insight into mechanisms of asthma Sheharyar, Durrani, Busse. Biological Therapy for Asthma. ACCP PCCSU Article | 03.15.11 Omalizumab (Anti-IgE) Biologics with action against IgE (omalizumab) Biologic mechanism: Mab against IgE; decreases IgE Cytokines levels; results in down-regulation of IgE receptor IL-4 and/or IL-13 Patient subsets: persistent asthma selected for IL-5 specific IgE to perennial allergen, total serum IgE in Chemokine Receptors specified range CCR3 Benefits: 8 trials (n=3429) Rodrigo. Chest 2011 139:28 CXCR2 decreases in exacerbations, dose of inhaled and oral Transcription Factors corticosteroids, hospitalizations PPARs (peroxisome proliferator-activated receptors) improvement in QOL when used as add-on Rx Prostaglandin Receptors no improvement in lung function. CRTH2 6 1 11/30/2011 IL-4 Modifiers IL-13 Altrakincept Solubilized IL-4 Failed to show efficacy in large phase Pleiotropic cytokine of Th2 cells, promotes IgE receptor fragment, 3 trial. production neutralizes IL-4 Adcock et al (2008) May contribute to key features of asthma Pascolizumab Monoclonal Ab Phase 2 study of pascolizumab IL-13 production inhibited by inhaled glucocorticoids against IL- 4 discontinued because of inefficacy.
    [Show full text]
  • Biological Therapies for Atopic Dermatitis: an Update (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 1061-1067, 2019 Biological therapies for atopic dermatitis: An update (Review) DIANA DELEANU1-3 and IRENA NEDELEA1,2 1Allergology and Immunology Discipline, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400058 Cluj-Napoca; Departments of 2Allergy and 3Internal Medicine, ‘Professor Doctor Octavian Fodor’ Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania Received July 6, 2018; Accepted August 22, 2018 DOI: 10.3892/etm.2018.6989 Abstract. Severe atopic dermatitis, which affects both adults in low-income countries (3). Furthermore, the past decades and children, is a debilitating disorder with a significant decline brought a 2-3-fold increase in prevalence in industrialized of patients' quality of life. Although aetiopathogenic factors countries (3). Generally AD onset is in early childhood, as are currently a topic of study and interpretation, the main one of the first steps of the ‘atopic march’, which describes the features of atopic eczema are skin barrier disturbance and natural history of atopic manifestations, and it is character- immune dysregulation. Severe refractory disease that fails to ized by xerotic skin and acute flare-ups of intensely pruritic improve with conventional therapy may benefit from biologic eczematous lesions (4). Recent studies recognize a predilection therapy. Progress in understanding immunopathology of atopic of AD for persistence in adulthood, with a lifetime prevalence dermatitis have allowed identification of therapeutic molecular accounting for 34.1% (5). Early onset, allergic rhinitis and targets in the field of biological therapy. We reviewed the hand eczema in childhood are high-risk factors for persistent different biological treatments with a focus on novel targeted AD (5).
    [Show full text]
  • Atopic Dermatitis (AD)
    This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by education grants from AbbVie, Inc., Sanofi Genzyme and Regeneron Pharmaceuticals. © 2019 PRIME® Education, LLC. All Rights Reserved.. Overview This downloadable fact‐sheet provides an easy‐to‐follow collection of the latest evidence shaping the treatment and management of psoriasis (PsO) and atopic dermatitis (AD). Learn about validated tools, evidence‐based strategies, and new and emerging targeted therapies that can be incorporated in daily practice to improve outcomes for patients with these conditions. © 2019 PRIME® Education, LLC. All Rights Reserved.. 2 1 Learning Objectives • Identify major barriers to evidence‐based treatment and management in federal and public sectors • Implement appropriate methods for diagnosis and assessment of disease activity • Assess current evidence on targeted biologic and small‐molecule therapies to guide treatment decisions for patients with moderate to severe disease • Monitor treatment responses according to treat‐to‐target principles and methods • Apply current evidence and guidelines to inform treatment decisions for patients with inadequate responses to initial therapies • Incorporate patient‐reported outcomes and shared decision‐making into clinical practice • Apply effective strategies for multidisciplinary care coordination and shared patient management © 2019 PRIME® Education, LLC. All Rights Reserved.. 3 Accreditation In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team, and learners will receive 2.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
    [Show full text]
  • Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: a Free Assay Disguised As Total
    pharmaceutics Article Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total John Hood 1,*, Ignacio González-García 1 , Nicholas White 1, Leeron Marshall 1,2, Vincent F. S. Dubois 1 , Paolo Vicini 1,3 and Paul G. Baverel 1,4 1 Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge CB21 6GH, UK; [email protected] (I.G.-G.); [email protected] (N.W.); [email protected] (L.M.); [email protected] (V.F.S.D.); [email protected] (P.V.); [email protected] (P.G.B.) 2 Salford Royal Foundation Trust, Salford M6 8HD, UK 3 Confo Therapeutics, 9052 Ghent, Zwijnaarde, Belgium 4 Roche Pharma Research and Early Development, Clinical Pharmacology, Pharmaceutical Sciences, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland * Correspondence: [email protected]; Tel.: +44-1223-749-6288 Abstract: A sequential pharmacokinetic (PK) and pharmacodynamic (PD) model was built with Nonlinear Mixed Effects Modelling based on data from a first-in-human trial of a novel biologic, MEDI7836. MEDI7836 is a human immunoglobulin G1 lambda (IgG1λ-YTE) monoclonal antibody, Citation: Hood, J.; González-García, with an Fc modification to reduce metabolic clearance. MEDI7836 specifically binds to, and function- I.; White, N.; Marshall, L.; Dubois, ally neutralizes interleukin-13. Thirty-two healthy male adults were enrolled into a dose-escalation V.F.S.; Vicini, P.; Baverel, P.G. clinical trial. Four active doses were tested (30, 105, 300, and 600 mg) with 6 volunteers enrolled Pharmacokinetic-Pharmacodynamic per cohort. Eight volunteers received placebo as control.
    [Show full text]
  • Gist Right: Five Leading Dermatologists Balance Education and Engagement in New Web Series
    PRACTICAL DERMATOLOGY® NEWS << VOLUME 16, NO. 11 • NOVEMBER 2019 Gist Right: Five Leading Dermatologists Balance Education and Engagement in New Web Series Five leading dermatologists are taking on social >> media misinformation one YouTube video at a time. Doris Day, MD; Jeanine Downie, MD; Sabrina Fabi, MD; Ava Shamban, MD; and Ruth Tedaldi, MD are the faces—and the brains—of “The Gist,” a new web series aimed at giving dermatology patients the facts about aesthetic and medical conditions and treatments. “We were constantly seeing lots of social media presence that is not accurate or expert in nature. We talk about it all the time,” says Dr. Tedaldi. The physicians wanted to find a way to reach the masses with facts and science, rather than hype. The concept of a web-based discussion format program was born. “We were very motivated and very excited,” Dr. Tedaldi says. “Really what we want to do is open the field of aes- thetic medicine.” “We want to take the fright factor out of cosmetic derma- benefit of having not just one opinion; you have the five tology,” adds Dr. Downie. opinions. It’s very difficult to go see even one dermatologist, The team knew that producing the series would require but to be able to have access to five very educated derma- more resources than they could muster. They approached tologists?” Allergan, and the company agreed to support the program The panelists may not always reach consensus, but viewers to grow the market for everyone as a non-branded venue. “can find the truth somewhere in between,” Dr.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Novel Therapies for Eosinophilic Disorders
    Novel Therapies for Eosinophilic Disorders Bruce S. Bochner, MD KEYWORDS Eosinophil Therapies Antibodies Targets Pharmacology Biomarkers KEY POINTS A sizable unmet need exists for new, safe, selective, and effective treatments for eosinophil-associated diseases, such as hypereosinophilic syndrome, eosinophilic gastrointestinal disorders, nasal polyposis, and severe asthma. An improved panel of biomarkers to help guide diagnosis, treatment, and assessment of disease activity is also needed. An impressive array of novel therapeutic agents, including small molecules and biologics, that directly or indirectly target eosinophils and eosinophilic inflammation are undergoing controlled clinical trials, with many already showing promising results. A large list of additional eosinophil-related potential therapeutic targets remains to be pursued, including cell surface structures, soluble proteins that influence eosinophil biology, and eosinophil-derived mediators that have the potential to contribute adversely to disease pathophysiology. INTRODUCTION Eosinophilic disorders, also referred to as eosinophil-associated diseases, consist of a range of infrequent conditions affecting virtually any body compartment and organ.1 The most commonly affected areas include the bone marrow, blood, mucosal sur- faces, and skin, often with immense disease- and treatment-related morbidity, Disclosure Statement: Dr Bochner’s research efforts are supported by grants AI072265, AI097073 and HL107151 from the National Institutes of Health. He has current or recent consul- ting or scientific advisory board arrangements with, or has received honoraria from, Sanofi-A- ventis, Pfizer, Svelte Medical Systems, Biogen Idec, TEVA, and Allakos, Inc. and owns stock in Allakos, Inc. and Glycomimetics, Inc. He receives publication-related royalty payments from Elsevier and UpToDate and is a coinventor on existing and pending Siglec-8-related patents and, thus, may be entitled to a share of future royalties received by Johns Hopkins University on the potential sales of such products.
    [Show full text]
  • What's New in Eczema Management
    What’s New in Eczema Management: Practice Pearls for the Family Physician This educational activity is jointly provided by the North Carolina Academy of Family Physicians (NCAFP) and Spire Learning. This activity is supported by an educational grant from Pfizer Inc. What’s New in Eczema Management: Practice Pearls for the Family Physician PROGRAM OVERVIEW This live meeting series will address the latest in the care and management of pediatric and adult dermatitis as well as strategies to individualize treatment. TARGET AUDIENCE Family physicians LEARNING OBJECTIVES At the conclusion of this live activity, family physicians should be better able to: • Recognize the clinical features and characteristic age distribution patterns of atopic dermatitis (AD) • Describe the role of skin barrier dysfunction, immune dysregulation, and environmental factors in the pathogenesis of AD • Individualize AD management regimens according to age, location, disease severity, response to treatment, and quality-of-life (QOL) concerns • Educate patients and families about the safe and appropriate use of skin-directed therapies for the treatment of AD ACCREDITATION AND DISCLAIMER STATEMENTS This live activity, What’s New in Eczema Management: Practice Pearls for the Family Physician has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AMA/AAFP Equivalency: AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.
    [Show full text]
  • Biologics in Asthma
    Biologics in Asthma: Present andPresenter Future of Flavia Hoyte,Reproduction MD Associate Professorfor of Medicine FellowshipProperty Training Program Director DivisionNot of Allergy and Immunology National Jewish Health and University of Colorado Disclosures Clinical investigator for GSK, TEVA, and Astra‐ Zeneca. Presenter of Reproduction for Property Not Learning objectives 1. Discuss current approaches to the management of moderate to severe asthma in adult patients. Presenter of 2. Describe new and emergingReproduction biologics for for the managementProperty of moderate to severe asthma. Not Asthma: A Highly Prevalent and Often Inadequately Controlled Disease 24+ million people in the US have asthma.1 17.72 million adults have asthma.Presenter1 of Reproduction 8.86 million adults havefor inadequately 39% of adults with Propertycontrolled asthma.2 1.33 million adults active asthma use Not have inadequately long‐term control controlled asthma medications.3 with eosinophilia.4 1. Centers for Disease Control and Prevention (CDC). Most Recent Asthma Data (2014 data). Accessed June 2016. 2. CDC. Uncontrolled asthma among persons with current asthma. Accessed June 2016. 3. CDC. Use of long‐term control medication among persons with active asthma. Accessed June 2016. 4. McGrath KW et al. Am J Respir Crit Care Med. 2012;185:612‐619. Paradigm Shift to a More Personalized Approach to Asthma Therapy Presenter of Reproduction for Property Not Dunn RM and Wechsler ME. Clinical Pharmacology and Therapeutics 2015; 97(1): 55‐65. Immunopathology of Asthma Presenter of Reproduction for Property Not Pelaia G, et al. Mediators Inflamm 2015:879783. doi: 10.1155/2015/879783. Epub 2015 Mar 23. Presenter of Reproduction for Property Not Katial et al.
    [Show full text]
  • Pediatric Dermatology at the 2021 Virtual SID Annual Meeting May 3-7, 2021
    Pediatric Dermatology at the 2021 Virtual SID Annual Meeting May 3-7, 2021 LIVE SESSIONS Tuesday, May 4th Plenary Lecture Session I (10:30 – 11:30a ET) Abstract #693: Gut dysbiosis plays a role in the development of alopecia areata A. R. Abdelaziz, J. Chen, B. N. Sallee, E. H. Wang, Z. Dai, E. Loesch, R. Perez-Lorenzo, L. A. Bordone, A. M. Christiano Abstract #209: Epidermal interferon production is positively regulated by Staphylococcus aureus in SLE and involves the STING pathway S. Sirobhushanam, M. K. Sarkar, H. Stickney, J. Banfield, J. E. Gudjonsson, J. M. Kahlenberg Abstract #646: Antimicrobial Perforin-2 in chronic wounds correlates with healing outcomes V. Chen, R. C. Stone, J. Burgess, N. Strbo, I. Pastar, M. Tomic-Canic Wednesday, May 5th American Dermato-Epidemiology Network (ADEN) Annual Meeting (8:00 – 9:30p ET) Abstract #323: Access to dermatologic care in urban underserved communities L. Roberson, S. Collier Plenary Lecture Session II (10:30 – 11:30a ET) Abstract #026: CXCR4+ skin-resident natural killer T cells participate in cutaneous allergic inflammation in atopic dermatitis Z. Sun, J. Kim, S. Kim, K. Zhang, H. Kim, S. Kim, K. Lee, T. S. Kupper, C. Park Abstract #097: Adipose triglyceride lipase dependent adipocyte lipolysis inhibits dermal fibrosis E. A. Caves, V. Lei, V. Horsley Pediatric Dermatology Session - PeDRA (12:30 – 2:00p ET) Abstract #150: Peripheral nervous system degeneration in patients with xeroderma pigmentosum T. Lehky, P. Sackstein, D. Tamura, M. Quezado, T. Wu, S.G. Khan, N.J. Patronas, E. Wiggs, C.C. Brewer, J.J. DiGiovanna, K.H.
    [Show full text]
  • Evaluation and Treatment of Patients with Severe Asthma
    Evaluation and Treatment of Patients with Severe Asthma Paul M. O’Byrne, MD Associate Professor of Pediatrics EJ Moran Campbell Professor of Medicine Firestone Institute for Respiratory Health, St. Joseph’s Healthcare and McMaster University, Hamilton, Ontario, Canada Faculty Disclosure for Paul M. O’Byrne For the 12 months preceding this CME activity, I disclose the following types of financial relationships: Honoraria received from: AstraZeneca, Boehringer Ingelheim, Chiesi Ltd., GlaxoSmithKline, Takeda Pharmaceutical Company Consulted for: AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, Merck, Verona Pharma Held common stock in: None Research, clinical trial, or drug study funds received from: AIM, Amgen, AstraZeneca, Axcan Pharma Inc., Genentech, GlaxoSmithKline, Novartis, Ono Pharmaceutical I will be discussing products that are investigational or not labeled for the use under discussion. The Goals of Asthma Management Overall Asthma Control achieving reducing Current control Future risk defined by defined by Instability/ Symptoms Reliever use Exacerbations worsening Loss of Adverse effects Activity Lung function lung function of medication NAEPP. Expert Panel Report 3. 2007 Taylor DR, et al. Eur Respir J 2008; 32:545–554 Severe refractory asthma makes up 5-10% asthma population Uncontrolled asthma and high exacerbation risk despite maximal conventional therapy Evaluation of Severe Refractory Asthma • Adherence, adherence, adherence • Co-morbidities – Rhino-sinusitis – GERD – Obesity – Bronchiectasis – Vocal cord dysfunction • Smoking • Psychopathology • Persistent allergen/occupational exposure • Incorrect diagnosis • Severe refractory disease Canadian Consensus Guidelines Lougheed D, et al. Can Respir J 2012; 19:127-64 Asthma Phenotypes/Endotypes Wenzel SE. Pul Pharm Ther 2013; 26: 710 - 715 Asthma Phenotypes Haldar P, et al. Am J Respir Crit Care Med 2008; 178:218-24 Inflammatory Phenotype: Induced Sputum O’Byrne PM, Nair P.
    [Show full text]